Christopher L. Lotz is President & CFO at Qualigen Therapeutics, Inc. (QLGN). They have made 1 open-market trade across 1 company since 2021, most recently 2021-04-16.
CIK 0001812553
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $5K since 2021, never a sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| QLGN | 12,541 | — |
Shares reported on the most recent Form 4, priced at the 2021-04-19 close. 1 holding could not be priced and is excluded from the total.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| QLGN | BUY | 2021-04-16 | 2021-04-19 | $1.86 | $5K | N/A | N/A | N/A |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.